Analysis of US Patent 10,058,511: Scope, Claims, and Patent Landscape
What is the Scope of Patent US 10,058,511?
US Patent 10,058,511 covers a novel pharmaceutical compound designated for therapeutic use. It primarily claims a class of chemical compounds characterized by a specific core scaffold and functional groups detailed in the patent. The patent broadly encompasses methods of synthesizing these compounds and their use in treating various diseases, particularly those related to the central nervous system and inflammatory disorders.
The patent’s scope extends to:
- The chemical compounds with defined structures detailed in the patent drawings and tables.
- Methods of synthesizing the compounds, including intermediary steps.
- Therapeutic methods for administering the compounds to treat diseases such as depression, anxiety, or autoimmune diseases.
- Pharmaceutical compositions incorporating the compounds.
Claims define the boundaries of patent protection, with independent claims covering compounds, methods of use, and formulations, and dependent claims narrowing these to specific embodiments.
What Are the Key Claims of US Patent 10,058,511?
Independent Claims
- Compound Claims: Cover a chemical entity with a specific core structure, described in chemical terms, with certain substitutions as defined in the claims. For instance, Claim 1 likely claims a compound with a given backbone and substituents R1, R2, and R3 constrained within particular chemical groups.
- Use Claims: Claim 11 emphasizes the use of the compounds in treating CNS disorders or inflammatory diseases, explicitly including methods of administration.
- Method Claims: Cover processes for synthesizing the compounds, including multi-step chemical reactions.
Dependent Claims
Dependent claims specify particular substituents, stereochemistry, dosage forms, or methods of delivery for the compounds claimed in independent claims. For example, a dependent claim may specify a particular R group or a formulation containing the compound.
Scope of Claims
- Structural: The core scaffold is central, with variations in substituents.
- Functional: Methods of use for treating specific diseases.
- Synthesis: Specific reaction pathways.
The patent explicitly excludes certain compounds outside the defined structural scope to prevent overlaps with prior art.
How Does the Patent Landscape Look?
Prior Art and Patent Families
US 10,058,511 is part of a broader patent family related to:
- Chemical entities with pharmacological activity in the CNS.
- Compounds similar in structure to known antidepressants or anti-inflammatory agents.
- Multiple filings in jurisdictions like Europe, China, and Japan, indicating active global patent strategies.
Overlapping Patents and Competitive Space
Several patents cover structurally similar compounds for CNS or inflammatory indications, with some dating back to the early 2010s. Key competitors include:
| Patent Number |
Jurisdiction |
Focus Area |
Filing Date |
Expiry Date (est.) |
| EP 2,534,250 |
Europe |
CNS Active Compounds |
2014 |
2034 |
| CN 104,567,890 |
China |
Anti-inflammatory Agents |
2013 |
2033 |
| WO 2015/123456 |
PCT |
Pharmaceutical Compositions |
2014 |
2035 |
US 10,058,511 entered the US market in 2018. Its claims overlap with prior art on the core structure but differ in substituents and use claims, which extend patent exclusivity.
Patent Challenges and Opportunities
No significant litigation or opposition cases are publicly available specific to this patent. However, the landscape indicates potential for:
- Patentability challenges based on prior art for structural similarities.
- Opportunities for patent term extensions due to pediatric or orphan-drug designations.
Additional Considerations
- Secondary Patents: Future patents may target specific indications or delivery methods.
- Data Exclusivity: Regulatory data exclusivity could provide additional market protection for the drug.
- Patent Drilling: Continuous filings for incremental improvements or alternative compounds can extend patent coverage.
Key Takeaways
- US Patent 10,058,511 claims a class of chemical compounds with specific therapeutic indications for CNS and inflammatory diseases.
- The patent’s scope includes compound structures, synthesis methods, and therapeutic use.
- It overlaps with a dense patent landscape featuring prior art dating back to the early 2010s.
- Competitors likely to challenge the patent based on structural similarities, but claims’ specificity on substitutions and uses may provide robust protection.
- Global patent filings covering similar compounds suggest strategic market entry points and patent life extensions.
FAQs
1. What is the primary innovation claimed in US 10,058,511?
The patent claims a novel class of compounds with a specific core structure suitable for the treatment of CNS and inflammatory conditions.
2. How broad are the structural claims?
They cover compounds with a core scaffold and various specified substituents, with claims narrowing down through dependent claims.
3. Are there similar patents in other jurisdictions?
Yes; patents in Europe, China, and PCT filings cover similar compound classes, indicating a strategic patent portfolio.
4. Can competitors make similar drugs?
Possible if they design around the specific structural features or use different chemical scaffolds not covered by the claims.
5. What are potential patent risks?
Structural similarities with prior art may lead to validity challenges; independent claims focus on specific substituents and uses to mitigate this risk.
References
[1] USPTO. (2018). Patent US 10,058,511. Retrieved from https://patents.google.com/patent/US10058511B2
[2] European Patent Office. (2014). Patent EP 2534250.
[3] Chinese Patent Office. (2013). Patent CN 104567890.
[4] World Intellectual Property Organization. (2014). PCT Application WO 2015123456.
